Efficacy and Safety Profile of Celecoxib for Treating Advanced Cancers: A Meta-analysis of 11 Randomized Clinical Trials

• Published in: Clinical therapeutics Vol. 36; no. 8; pp. 1253 - 1263
• Main Authors: Chen, Jian, PharmD, PhD, Shen, Peng, MD, PhD, Zhang, Xiao-chen, PhD, Zhao, Meng-dan, MD, Zhang, Xing-guo, PharmD, PhD, Yang, Liu, MD, PhD
• Format: Journal Article
• Language: English
• Published: United States EM Inc USA 01.08.2014; Elsevier Limited
• Subjects: advanced cancer; Anemia - chemically induced; Anemia - epidemiology; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Apoptosis; Arthritis; Bias; Breast cancer; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Cardiovascular Diseases - chemically induced; Cardiovascular Diseases - epidemiology; celecoxib; Celecoxib - administration & dosage; Celecoxib - adverse effects; Clinical trials; Colorectal Neoplasms - drug therapy; Cyclooxygenase 2 Inhibitors - administration & dosage; Cyclooxygenase 2 Inhibitors - adverse effects; Disease-Free Survival; Drug therapy; efficacy; Endocrine therapy; Humans; Internal Medicine; Lung Neoplasms - drug therapy; Medical Education; Medical prognosis; Meta-analysis; Metastasis; Mortality; Ovarian cancer; Prostate cancer; Radiation therapy; Randomized Controlled Trials as Topic; Response rates; Risk Factors; safety; Sensitivity analysis; Studies; Survival Rate; Toxicity; advanced cancer; celecoxib; safety; efficacy

Abstract Purpose Evidence on the benefits of combining celecoxib, a cyclooxygenase-2 inhibitor, in treating advanced cancer is still controversial. This study aimed to establish the efficacy and safety profile of celecoxib in treating advanced cancers. Methods The PubMed, Embase, and Cochrane databa...